Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris
Psoriasis vulgaris is a common, chronic inflammatory skin disease with a prevalence of 1.5-2% in Western industrialized countries. A relevant percentage of patients suffer from moderate-to-severe psoriasis and experience a significant reduction in quality of life. The choice of an adequate therapy c...
Gespeichert in:
| Veröffentlicht in: | Dermatology (Basel) 2016-01, Vol.232 (4), p.385-406 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 406 |
|---|---|
| container_issue | 4 |
| container_start_page | 385 |
| container_title | Dermatology (Basel) |
| container_volume | 232 |
| creator | Kolios, Antonios G.A. Yawalkar, Nikhil Anliker, Mark Boehncke, Wolf-Henning Borradori, Luca Conrad, Curdin Gilliet, Michel Häusermann, Peter Itin, Peter Laffitte, Emmanuel Mainetti, Carlo French, Lars E. Navarini, Alexander A. |
| description | Psoriasis vulgaris is a common, chronic inflammatory skin disease with a prevalence of 1.5-2% in Western industrialized countries. A relevant percentage of patients suffer from moderate-to-severe psoriasis and experience a significant reduction in quality of life. The choice of an adequate therapy could help to prevent disease and exacerbation of comorbidity, which could increase quality of life, avoid hospitalization and avoid reduction of working days. The present guidelines are focused on the initiation and management of systemic therapies in cases of moderate-to-severe plaque-type psoriasis in adults to optimize treatment response, adherence and quality of life. This first version of the Swiss S1 guidelines presents therapeutic recommendations which are based on a systematic literature search as well as an informal expert consensus of dermatologists in Switzerland. |
| doi_str_mv | 10.1159/000445681 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_27322375</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1822470164</sourcerecordid><originalsourceid>FETCH-LOGICAL-c341t-52407d06d586585b925add964f3cdc80f98ef03ba0bff6d60f8b7de0c95c8e523</originalsourceid><addsrcrecordid>eNo90DFPwzAQBWALgSgUBnaEPMIQsJ3YcUZUQUGqBFILa-TY52JImuJLhPrvCWrpdDd87w2PkAvObjmXxR1jLMuk0vyAnPBM8KTQqTgcfsZ1opWSI3KK-DkwofPimIxEngqR5vKETOY_AZHOOZ32wUEdVoC0XdHuA-h8gx00wdJFBNM1sOpo6-krtjEYDEjf-3ppYsAzcuRNjXC-u2Py9viwmDwls5fp8-R-ltg0410iRcZyx5STWkktq0JI41yhMp9aZzXzhQbP0sqwynvlFPO6yh0wW0irQYp0TK63vevYfveAXdkEtFDXZgVtjyXXQmQ54yob6M2W2tgiRvDlOobGxE3JWfm3WbnfbLBXu9q-asDt5f9IA7jcgi8TlxD3YJf_BWu1bqM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1822470164</pqid></control><display><type>article</type><title>Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris</title><source>MEDLINE</source><source>Karger Journals Complete</source><creator>Kolios, Antonios G.A. ; Yawalkar, Nikhil ; Anliker, Mark ; Boehncke, Wolf-Henning ; Borradori, Luca ; Conrad, Curdin ; Gilliet, Michel ; Häusermann, Peter ; Itin, Peter ; Laffitte, Emmanuel ; Mainetti, Carlo ; French, Lars E. ; Navarini, Alexander A.</creator><creatorcontrib>Kolios, Antonios G.A. ; Yawalkar, Nikhil ; Anliker, Mark ; Boehncke, Wolf-Henning ; Borradori, Luca ; Conrad, Curdin ; Gilliet, Michel ; Häusermann, Peter ; Itin, Peter ; Laffitte, Emmanuel ; Mainetti, Carlo ; French, Lars E. ; Navarini, Alexander A.</creatorcontrib><description>Psoriasis vulgaris is a common, chronic inflammatory skin disease with a prevalence of 1.5-2% in Western industrialized countries. A relevant percentage of patients suffer from moderate-to-severe psoriasis and experience a significant reduction in quality of life. The choice of an adequate therapy could help to prevent disease and exacerbation of comorbidity, which could increase quality of life, avoid hospitalization and avoid reduction of working days. The present guidelines are focused on the initiation and management of systemic therapies in cases of moderate-to-severe plaque-type psoriasis in adults to optimize treatment response, adherence and quality of life. This first version of the Swiss S1 guidelines presents therapeutic recommendations which are based on a systematic literature search as well as an informal expert consensus of dermatologists in Switzerland.</description><identifier>ISSN: 1018-8665</identifier><identifier>EISSN: 1421-9832</identifier><identifier>DOI: 10.1159/000445681</identifier><identifier>PMID: 27322375</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Acitretin - therapeutic use ; Biological Factors - therapeutic use ; Consensus Guidelines ; Cyclosporine - therapeutic use ; Dermatology - standards ; Fumarates - therapeutic use ; Glucocorticoids - therapeutic use ; Humans ; Immunosuppressive Agents - therapeutic use ; Psoriasis - drug therapy ; Societies, Medical ; Switzerland ; Thalidomide - analogs & derivatives ; Thalidomide - therapeutic use</subject><ispartof>Dermatology (Basel), 2016-01, Vol.232 (4), p.385-406</ispartof><rights>2016 S. Karger AG, Basel</rights><rights>2016 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c341t-52407d06d586585b925add964f3cdc80f98ef03ba0bff6d60f8b7de0c95c8e523</citedby><cites>FETCH-LOGICAL-c341t-52407d06d586585b925add964f3cdc80f98ef03ba0bff6d60f8b7de0c95c8e523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,2429,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27322375$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kolios, Antonios G.A.</creatorcontrib><creatorcontrib>Yawalkar, Nikhil</creatorcontrib><creatorcontrib>Anliker, Mark</creatorcontrib><creatorcontrib>Boehncke, Wolf-Henning</creatorcontrib><creatorcontrib>Borradori, Luca</creatorcontrib><creatorcontrib>Conrad, Curdin</creatorcontrib><creatorcontrib>Gilliet, Michel</creatorcontrib><creatorcontrib>Häusermann, Peter</creatorcontrib><creatorcontrib>Itin, Peter</creatorcontrib><creatorcontrib>Laffitte, Emmanuel</creatorcontrib><creatorcontrib>Mainetti, Carlo</creatorcontrib><creatorcontrib>French, Lars E.</creatorcontrib><creatorcontrib>Navarini, Alexander A.</creatorcontrib><title>Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris</title><title>Dermatology (Basel)</title><addtitle>Dermatology</addtitle><description>Psoriasis vulgaris is a common, chronic inflammatory skin disease with a prevalence of 1.5-2% in Western industrialized countries. A relevant percentage of patients suffer from moderate-to-severe psoriasis and experience a significant reduction in quality of life. The choice of an adequate therapy could help to prevent disease and exacerbation of comorbidity, which could increase quality of life, avoid hospitalization and avoid reduction of working days. The present guidelines are focused on the initiation and management of systemic therapies in cases of moderate-to-severe plaque-type psoriasis in adults to optimize treatment response, adherence and quality of life. This first version of the Swiss S1 guidelines presents therapeutic recommendations which are based on a systematic literature search as well as an informal expert consensus of dermatologists in Switzerland.</description><subject>Acitretin - therapeutic use</subject><subject>Biological Factors - therapeutic use</subject><subject>Consensus Guidelines</subject><subject>Cyclosporine - therapeutic use</subject><subject>Dermatology - standards</subject><subject>Fumarates - therapeutic use</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Psoriasis - drug therapy</subject><subject>Societies, Medical</subject><subject>Switzerland</subject><subject>Thalidomide - analogs & derivatives</subject><subject>Thalidomide - therapeutic use</subject><issn>1018-8665</issn><issn>1421-9832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo90DFPwzAQBWALgSgUBnaEPMIQsJ3YcUZUQUGqBFILa-TY52JImuJLhPrvCWrpdDd87w2PkAvObjmXxR1jLMuk0vyAnPBM8KTQqTgcfsZ1opWSI3KK-DkwofPimIxEngqR5vKETOY_AZHOOZ32wUEdVoC0XdHuA-h8gx00wdJFBNM1sOpo6-krtjEYDEjf-3ppYsAzcuRNjXC-u2Py9viwmDwls5fp8-R-ltg0410iRcZyx5STWkktq0JI41yhMp9aZzXzhQbP0sqwynvlFPO6yh0wW0irQYp0TK63vevYfveAXdkEtFDXZgVtjyXXQmQ54yob6M2W2tgiRvDlOobGxE3JWfm3WbnfbLBXu9q-asDt5f9IA7jcgi8TlxD3YJf_BWu1bqM</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Kolios, Antonios G.A.</creator><creator>Yawalkar, Nikhil</creator><creator>Anliker, Mark</creator><creator>Boehncke, Wolf-Henning</creator><creator>Borradori, Luca</creator><creator>Conrad, Curdin</creator><creator>Gilliet, Michel</creator><creator>Häusermann, Peter</creator><creator>Itin, Peter</creator><creator>Laffitte, Emmanuel</creator><creator>Mainetti, Carlo</creator><creator>French, Lars E.</creator><creator>Navarini, Alexander A.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160101</creationdate><title>Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris</title><author>Kolios, Antonios G.A. ; Yawalkar, Nikhil ; Anliker, Mark ; Boehncke, Wolf-Henning ; Borradori, Luca ; Conrad, Curdin ; Gilliet, Michel ; Häusermann, Peter ; Itin, Peter ; Laffitte, Emmanuel ; Mainetti, Carlo ; French, Lars E. ; Navarini, Alexander A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c341t-52407d06d586585b925add964f3cdc80f98ef03ba0bff6d60f8b7de0c95c8e523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acitretin - therapeutic use</topic><topic>Biological Factors - therapeutic use</topic><topic>Consensus Guidelines</topic><topic>Cyclosporine - therapeutic use</topic><topic>Dermatology - standards</topic><topic>Fumarates - therapeutic use</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Psoriasis - drug therapy</topic><topic>Societies, Medical</topic><topic>Switzerland</topic><topic>Thalidomide - analogs & derivatives</topic><topic>Thalidomide - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kolios, Antonios G.A.</creatorcontrib><creatorcontrib>Yawalkar, Nikhil</creatorcontrib><creatorcontrib>Anliker, Mark</creatorcontrib><creatorcontrib>Boehncke, Wolf-Henning</creatorcontrib><creatorcontrib>Borradori, Luca</creatorcontrib><creatorcontrib>Conrad, Curdin</creatorcontrib><creatorcontrib>Gilliet, Michel</creatorcontrib><creatorcontrib>Häusermann, Peter</creatorcontrib><creatorcontrib>Itin, Peter</creatorcontrib><creatorcontrib>Laffitte, Emmanuel</creatorcontrib><creatorcontrib>Mainetti, Carlo</creatorcontrib><creatorcontrib>French, Lars E.</creatorcontrib><creatorcontrib>Navarini, Alexander A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Dermatology (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kolios, Antonios G.A.</au><au>Yawalkar, Nikhil</au><au>Anliker, Mark</au><au>Boehncke, Wolf-Henning</au><au>Borradori, Luca</au><au>Conrad, Curdin</au><au>Gilliet, Michel</au><au>Häusermann, Peter</au><au>Itin, Peter</au><au>Laffitte, Emmanuel</au><au>Mainetti, Carlo</au><au>French, Lars E.</au><au>Navarini, Alexander A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris</atitle><jtitle>Dermatology (Basel)</jtitle><addtitle>Dermatology</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>232</volume><issue>4</issue><spage>385</spage><epage>406</epage><pages>385-406</pages><issn>1018-8665</issn><eissn>1421-9832</eissn><abstract>Psoriasis vulgaris is a common, chronic inflammatory skin disease with a prevalence of 1.5-2% in Western industrialized countries. A relevant percentage of patients suffer from moderate-to-severe psoriasis and experience a significant reduction in quality of life. The choice of an adequate therapy could help to prevent disease and exacerbation of comorbidity, which could increase quality of life, avoid hospitalization and avoid reduction of working days. The present guidelines are focused on the initiation and management of systemic therapies in cases of moderate-to-severe plaque-type psoriasis in adults to optimize treatment response, adherence and quality of life. This first version of the Swiss S1 guidelines presents therapeutic recommendations which are based on a systematic literature search as well as an informal expert consensus of dermatologists in Switzerland.</abstract><cop>Basel, Switzerland</cop><pmid>27322375</pmid><doi>10.1159/000445681</doi><tpages>22</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1018-8665 |
| ispartof | Dermatology (Basel), 2016-01, Vol.232 (4), p.385-406 |
| issn | 1018-8665 1421-9832 |
| language | eng |
| recordid | cdi_pubmed_primary_27322375 |
| source | MEDLINE; Karger Journals Complete |
| subjects | Acitretin - therapeutic use Biological Factors - therapeutic use Consensus Guidelines Cyclosporine - therapeutic use Dermatology - standards Fumarates - therapeutic use Glucocorticoids - therapeutic use Humans Immunosuppressive Agents - therapeutic use Psoriasis - drug therapy Societies, Medical Switzerland Thalidomide - analogs & derivatives Thalidomide - therapeutic use |
| title | Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T22%3A35%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Swiss%20S1%20Guidelines%20on%20the%20Systemic%20Treatment%20of%20Psoriasis%20Vulgaris&rft.jtitle=Dermatology%20(Basel)&rft.au=Kolios,%20Antonios%20G.A.&rft.date=2016-01-01&rft.volume=232&rft.issue=4&rft.spage=385&rft.epage=406&rft.pages=385-406&rft.issn=1018-8665&rft.eissn=1421-9832&rft_id=info:doi/10.1159/000445681&rft_dat=%3Cproquest_pubme%3E1822470164%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1822470164&rft_id=info:pmid/27322375&rfr_iscdi=true |